Watch for Continued Gains in Shares of PerkinElmer Inc.

PerkinElmer Inc. PKI traded at a new 12-month high today of $199.57. Approximately 157,000 shares have changed hands today, as compared to an average 30-day volume of 1.1 million shares.

PerkinElmer Inc. share prices have moved between a 12-month high of $199.57 and a 12-month low of $119.95 and are now trading 66% above that low price at $198.91 per share.

PerkinElmer provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments: diagnostics, which includes prenatal screening and infectious-disease testing, and discovery and analytical solutions, composed of life science, industrial, environmental, and food applications. PerkinElmer offers products and services ranging from genetic screening to environmental analytical tools.

PerkinElmer Inc. is currently priced 36.7% above its average consensus analyst price target of $125.91.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. The content was purely for informational purposes only and not intended to be investing advice.

Image Sourced from Pixabay